{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:40:21Z","timestamp":1790894421606,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.rdc.2018.01.003","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T09:47:42Z","timestamp":1522748862000},"page":"361-370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Applied Bayesian Methods in the Rheumatic Diseases"],"prefix":"10.1016","volume":"44","author":[{"given":"Sindhu R.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Granton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian A.","family":"Hawker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rdc.2018.01.003_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrd1927","article-title":"Bayesian clinical trials","volume":"5","author":"Berry","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.rdc.2018.01.003_bib2","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A\u00a0randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2018.01.003_bib3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/jech.52.5.318","article-title":"Clinical significance not statistical significance: a simple Bayesian alternative to p values","volume":"52","author":"Burton","year":"1998","journal-title":"J\u00a0Epidemiol Community Health"},{"key":"10.1016\/j.rdc.2018.01.003_bib4","series-title":"The grand design","author":"Hawking","year":"2010"},{"key":"10.1016\/j.rdc.2018.01.003_bib5","series-title":"Statistics: a Bayesian perspective","author":"Berry","year":"1996"},{"key":"10.1016\/j.rdc.2018.01.003_bib6","series-title":"Health measurement scales. A practical guide to their development and Use 4th edition","author":"Streiner","year":"2008"},{"key":"10.1016\/j.rdc.2018.01.003_bib7","series-title":"Guidance for the use of Bayesian statistics in medical device clinical trials","author":"Campbell","year":"2010"},{"issue":"11","key":"10.1016\/j.rdc.2018.01.003_bib8","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.3899\/jrheum.140006","article-title":"The effect of male sex on survival in systemic sclerosis","volume":"41","author":"Hussein","year":"2014","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2018.01.003_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0197-2456(95)00072-0","article-title":"Prime time for Bayes","volume":"16","author":"Kadane","year":"1995","journal-title":"Control Clin Trials"},{"issue":"5444","key":"10.1016\/j.rdc.2018.01.003_bib10","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1126\/science.286.5444.1460","article-title":"Bayes offers a 'new' way to make sense of numbers","volume":"286","author":"Malakoff","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.rdc.2018.01.003_bib11","first-page":"370","article-title":"An essay towards solving a problem in the doctrine of chances","volume":"53","author":"Bayes","year":"1763","journal-title":"Philos T Roy Soc"},{"issue":"3\/4","key":"10.1016\/j.rdc.2018.01.003_bib12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2307\/2333180","article-title":"Studies in the history of probability and statistics: IX. Thomas Bayes's essay towards solving a problem in the doctrine of chances","volume":"45","author":"Barnard","year":"1958","journal-title":"Biometrika"},{"issue":"4","key":"10.1016\/j.rdc.2018.01.003_bib13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jclinepi.2009.06.003","article-title":"Methods to elicit beliefs for Bayesian priors: a systematic review","volume":"63","author":"Johnson","year":"2010","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.rdc.2018.01.003_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jclinepi.2008.07.006","article-title":"Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials","volume":"62","author":"Wijeysundera","year":"2009","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"17","key":"10.1016\/j.rdc.2018.01.003_bib15","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/sim.4780131702","article-title":"Helping doctors to draw appropriate inferences from the analysis of medical studies","volume":"13","author":"Burton","year":"1994","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.rdc.2018.01.003_bib16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3899\/jrheum.071169","article-title":"Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma","volume":"36","author":"Johnson","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2018.01.003_bib17","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3899\/jrheum.110013","article-title":"Bayesian inference: statistical gimmick or added value?","volume":"38","author":"Johnson","year":"2011","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2018.01.003_bib18","first-page":"1125","article-title":"Amitriptyline to relieve pain in juvenile idiopathic arthritis: a pilot study using Bayesian meta-analysis of multiple N-of-1 clinical trials","volume":"34","author":"Huber","year":"2007","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2018.01.003_bib19","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3899\/jrheum.100632","article-title":"Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and Idiopathic PAH. Belief elicitation for Bayesian priors","volume":"38","author":"Johnson","year":"2011","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2018.01.003_bib20","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3899\/jrheum.110765","article-title":"Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease","volume":"39","author":"Johnson","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2018.01.003_bib21","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3899\/jrheum.100665","article-title":"Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian meta-analysis","volume":"38","author":"Launois","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2018.01.003_bib22","series-title":"Bayesian approaches to clinical trials and health care evaluation","author":"Spiegelhalter","year":"2004"},{"issue":"6","key":"10.1016\/j.rdc.2018.01.003_bib23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2018.01.003_bib24","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3899\/jrheum.111345","article-title":"Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United Kingdom","volume":"39","author":"Guyot","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2018.01.003_bib25","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1136\/ard.2008.093161","article-title":"Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences","volume":"68","author":"Bernatsky","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2018.01.003_bib26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00296-010-1591-2","article-title":"Surveillance of systemic autoimmune rheumatic diseases using administrative data","volume":"31","author":"Bernatsky","year":"2011","journal-title":"Rheumatol Int"},{"issue":"7","key":"10.1016\/j.rdc.2018.01.003_bib27","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/art.23018","article-title":"Classification criteria in rheumatic diseases: a review of methodologic properties","volume":"57","author":"Johnson","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2018.01.003_bib28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/acr.20684","article-title":"Validation of potential classification criteria for systemic sclerosis","volume":"64","author":"Johnson","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.rdc.2018.01.003_bib29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/art.21714","article-title":"Scleroderma treatment differs between experts and general rheumatologists","volume":"55","author":"Pope","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5 Suppl 61","key":"10.1016\/j.rdc.2018.01.003_bib30","first-page":"S160","article-title":"Use of methotrexate in patients with scleroderma and mixed connective tissue disease","volume":"28","author":"Kowal-Bielecka","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2018.01.003_bib31","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ajmg.c.31533","article-title":"Alternative designs for clinical trials in rare diseases","volume":"172","author":"Abrahamyan","year":"2016","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.rdc.2018.01.003_bib32","unstructured":"Willan A. Why a Bayesian be? In: SSo, editor. Wolfville (Canada): 2011."}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X18300036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X18300036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:16:10Z","timestamp":1760181370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X18300036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0889857X18300036"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2018.01.003","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Applied Bayesian Methods in the Rheumatic Diseases","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2018.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}